IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Ausnutria: Blue Orca’s Attack Lacks Heft

China Feihe IPO: Valuation Is Good for You

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/china-feihe" target="_blank" data-smartkarma-citation="entities:24413:1" rel="noopener">China Feihe (FEIHE HK)</a> is the leading player in the China IMF (infant milk formula) market as measured by retail sales value in 2018, according to Frost &amp; Sullivan. Feihe has filed for a Hong Kong IPO to raise a potential $1 billion, according to Bloomberg. </p><div class="content-highlight"><p>Notwithstanding the headwinds due to declining birth rates and an increase in cross-border purchases, Feihe has an attractive market opportunity as it is overweight the high-growth and high-margin super-premium IMF segment. Overall, we believe that Feihe’s equity story offers more positives than negatives and we would place it on our must-look IPO watchlist.</p></div>

China Feihe (FEIHE HK) is the leading player in the China IMF (infant milk formula) market as measured by retail sales value in 2018, according to Frost &amp; Sullivan. Feihe has filed for a Hong Kong IPO to raise a potential $1 billion, according to Bloomberg. Notwithstanding the headwinds due to declining birth rates and an increase in cross-border purchases, Feihe has an attractive market opportunity as it is overweight the high-growth and high-margin super-premium IMF segment. Overall, we believe that Feihe’s equity story offers more positives than negatives and we would place it on our must-look IPO watchlist.

Inner Mongolia Yili Industrial Group (A) (600887 CH)

China Feihe IPO Preview: The Winning Formula?